Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
0.82 1.02 1.07 1.25
P/FCF ratio
7.04 7.52 9.07 9.77
P/Operating CF
15.48 17.87 40.20 48.38
P/B ratio
0.76 0.99 1.06 1.30
EV/Sales
1.90 1.93 1.93 2.10
EV/EBITDA
8.75 9.01 9.55 11.39
EV/FCF
16.38 14.27 16.35 16.36
Current Ratio
1.35 1.38 1.60 1.58
Net Debt/EBITDA
17.63 22.80 21.03 18.37
Debt/Equity
1.07 0.98 0.98 0.94
Earnings Yield
(31.25%) (23.81%) (1.95%) (2.27%)
Free Cash Flow Yield
14.20% 13.30% 11.03% 10.23%
Free Cash Flow per Share
0.55 0.55 0.23 0.29
Book value per Share
13.07 12.57 12.69 12.26
Free Cash Flow
646.00 640.40 268.00 336.20
EV/EBIT
0.00 0.00 201.94 0.00
Other line items

Show all line items

Columns are period end dates